Checkpoint Therapeutics (CKPT) Expected to Announce Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT opened at $4.06 on Wednesday. The firm’s 50-day moving average price is $3.27 and its 200-day moving average price is $3.23. The company has a market capitalization of $198.26 million, a PE ratio of -2.21 and a beta of 1.41. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50.

Insider Buying and Selling

In related news, CEO James F. Oliviero III sold 10,331 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. This represents a 0.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. This represents a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,674 shares of company stock valued at $336,011 in the last ninety days. 2.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CKPT shares. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. D. Boral Capital reissued a “buy” rating and set a $4.80 price objective (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, Lake Street Capital reiterated a “hold” rating and set a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.